4c Biomed

4C Biomed is a private, preclinical-stage biotech company developing novel cancer immunotherapies through its proprietary discovery platform. The company's core technology utilizes autologous patient-derived tumor and immune cell systems to functionally identify and validate new drug targets with high clinical relevance. Its most advanced asset, anti-4CB1, is a fully human monoclonal antibody designed to block the HVEM-BTLA/CD160 inhibitory axis and is progressing towards a planned Phase I trial in 2026. The company operates as a platform and therapeutics developer, seeking partnerships to leverage its target discovery capabilities.

A patient-derived, autologous cell-based discovery platform that combines patient tumor cultures/digests with matched immune cells (TILs/PBMCs) for high-throughput immunological screening and functional target identification, integrated with clinical data annotation.

4C Biomed competes in the crowded next-generation immuno-oncology checkpoint space. Its lead candidate faces potential competition from other companies developing therapies targeting the HVEM/BTLA/CD160 axis. Its platform competes with other target discovery technologies in biotech and academia.